



December 19, 2008

MannKind to Present at the 27th Annual J.P. Morgan Healthcare Conference

VALENCIA, Calif., Dec. 19 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 1:30 PM (PST) at the Westin St. Francis in San Francisco. In addition to this presentation, the Company will host a breakfast meeting for investors and analysts at 8:00 AM (PST) on January 14th at a location to be announced.

Interested parties can access links to live web casts of the presentations from the Investor Relations section of the Company's website at <http://www.mannkindcorp.com>. Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at <https://www.mannkindcorp.com> to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.

SOURCE MannKind Corporation CONTACT:

Matthew J. Pfeffer,
Corporate Vice President and Chief Financial Officer
of MannKind Corporation,
+1-661-775-5300,
mpfeffer@mannkindcorp.com

Web Site: <http://www.mannkindcorp.com>